

08/03/01

Jc965
U.S. PTO

08-06-01

A

UTILITY PATENT APPLICATION
TRANSMITTAL

Attorney Docket No.

P30693C4C1

First Named Inventor

MacPhee, et al.

For new nonprovisional applications under 37 CFR 1.53(b))

"EXPRESS MAIL CERTIFICATE"

"EXPRESS MAIL" MAILING LABEL NUMBER EL737870959US DATE OF DEPOSIT: 03 August 2001

I hereby certify that this paper or fee and the papers indicated as being transmitted herewith are being deposited with the United States Postal Service "Express Mail Post Office to Addressee" service under 37 CFR 1.10 on the date and with the Mailing Label Number indicated above and addressed to:
The Assistant Commissioner for Patents, Box Patent Application, Washington, D.C. 20231.

NAME OF PERSON MAILING PAPER OR FEE

(TYPE OR PRINT) Sabrina Smith

SIGNATURE

Sabrina Smith11092 U.S. PTO
09/922067

08/03/01

APPLICATION ELEMENTS	
See MPEP chapter 600 concerning utility patent application contents.	
1. <input checked="" type="checkbox"/> The Commissioner is hereby authorized to charge indicated fees and credit any overpayments to Deposit Account No. 19-2570 <input checked="" type="checkbox"/> General Authorization to charge any and all fees under 37 CFR 1.16 or 1.17, including petitions for extensions of time, relating to this application. (37 CFR 1.136(a)(3)) (Submit an original, and a duplicate for fee processing)	7. <input checked="" type="checkbox"/> The Title of the Invention: Lipoprotein Associated Phospholipase A2 Inhibitors Thereof and Use of the Same in Diagnosis and Therapy
2. <input checked="" type="checkbox"/> The total fee is calculated as shown below: Basic Filing fee \$710.00 Total Claims 4 - 20 = 0 x \$18 \$.00 Independent Claims 2 - 3 = 0 x \$80 \$.00 <input type="checkbox"/> Multiple Dependent Claim present. \$270 \$.00 TOTAL FILING FEE \$710.00 <input checked="" type="checkbox"/> Cancel in this application original claims <u>1</u> to <u>24</u> of the prior application before calculating the filing fee. <input checked="" type="checkbox"/> Charge \$710.00 to the above indicated Deposit Account.	8. <input checked="" type="checkbox"/> Nucleotide and/or Amino Acid Sequence Submission a. <input type="checkbox"/> Computer Readable Copy b. <input type="checkbox"/> Paper Copy (identical to computer copy) c. <input type="checkbox"/> Statement verifying identity of above copies d. <input checked="" type="checkbox"/> Use the identical computer-readable form filed in Application No. <u>09/193,130</u> , filed <u>November 17, 1998</u> as the computer-readable form for the instant application. (37 CFR 1.821(e))
3a. <input checked="" type="checkbox"/> Specification excluding Drawings [Total Pages] <u>23</u> 3b. <input checked="" type="checkbox"/> Abstract on a separate sheet [Total Pages] <u>1</u> 4. <input checked="" type="checkbox"/> Drawing(s) (35 USC 113) [Total Sheets] <u>2</u>	9. <input type="checkbox"/> Information Disclosure Statement (IDS) b. <input type="checkbox"/> PTO-1449 c. <input type="checkbox"/> Copies of all IDS Citations 10. <input type="checkbox"/> Assignment Papers (cover sheet & document(s))
5. <input checked="" type="checkbox"/> Declaration and Power of Attorney [Total Pages] <u>6</u> a. <input type="checkbox"/> Newly executed (original or copy) b. <input checked="" type="checkbox"/> Copy from a prior application (37 CFR 1.63(d)) (for continuation/divisional with Box 17a completed) c. <input type="checkbox"/> Unsigned Declaration i. <input type="checkbox"/> DELETION OF INVENTOR(S) Signed statement attached deleting inventor(s) named in the prior application, see 37 CFR 1.63(d)(2) and 1.33(b).	11. Prior Application is Assigned to: <u>SmithKline Beecham plc</u> (for continuation/divisional with Box 17a completed)
6. <input checked="" type="checkbox"/> Incorporation By Reference (useable if Box 5b is checked) The entire disclosure of the prior application, from which a copy of the oath or declaration is supplied under Box 5b, is considered as being part of the disclosure of the accompanying application and is hereby incorporated by reference therein.	12. <input checked="" type="checkbox"/> Preliminary Amendment [Total Pages]
17. <input checked="" type="checkbox"/> Priority Information, check appropriate box and supply the requisite information a. The accompanying application is a <input checked="" type="checkbox"/> Continuation <input type="checkbox"/> Divisional <input type="checkbox"/> Continuation-in-part (CIP) of prior application No: <u>09/193,130</u> filed <u>November 17, 1998</u> . b. <input type="checkbox"/> Benefit is claimed under Title 35, United States Code, Section 119(e) of the following Provisional Applications: Application No. filed . c. <input checked="" type="checkbox"/> Please amend the specification by inserting before the first line the sentence: (37 CFR 1.78) This is a Continuation of CPA application <u>09/193,130</u> , filed on <u>November 28, 2000</u> , which is a Continuation of Serial No. <u>09/193,130</u> filed <u>November 17, 1998</u> , which is a Continuation Serial No. <u>08/387,858</u> , filed <u>February 24, 1995</u> , now U.S. Patent Number <u>5,981,252</u> , which is a <u>\$371</u> of International Application No. <u>PCT/GB94/01374</u> filed <u>June 24, 1994</u> , which claims priority of Great Britain Application Nos. <u>GB 9313144.9</u> filed <u>June 25, 1993</u> , and <u>9400413.2</u> , filed <u>January 11, 1994</u> .	
18. CUSTOMER NUMBER: 20462	19. RESPECTFULLY SUBMITTED,
Address GLAXOSMITHKLINE Corporate Intellectual Property - UW2220 P.O. Box 1539 King of Prussia, PA 19406-0939 Telephone (610) 270-5219 Fax (610) 270-5090	Signature <u>William T. Han</u> Name William T. Han Registration No. 34,344

CERTIFICATE OF MAILING

I HEREBY CERTIFY THAT THIS CORRESPONDENCE IS BEING
DEPOSITED WITH THE UNITED STATES POSTAL SERVICE WITH
SUFFICIENT POSTAGE AS FIRST-CLASS MAIL IN AN ENVELOPE
ADDRESSED TO: ASSISTANT COMMISSIONER FOR PATENTS,
WASHINGTON, D.C. 20231, ON 03 August 2001

William T. Han
8/3/2001
DATE

Attorney Docket No. P30693C4X1

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: MacPhee, et al. 03 August 2001
Serial No.: 09/193,130 Group Art Unit No.: 1652
Filed: November 17, 1998 Examiner: M. Rao
For: Lipoprotein Associated Phospholipase A2 Inhibitors Thereof and Use of the Same in
Diagnosis and Therapy

TRANSMITTAL LETTER

Applicants are concurrently filing a continuation application that is based on the present
Application Serial No. 09/193,130 filed November 17, 1998.

EXTENSION OF TIME PETITION

Applicants hereby petition for an extension of time for response from the date of the
Examiner's action as needed, the fee being as follows:

<input type="checkbox"/>	one month extension.....	\$ 110
<input type="checkbox"/>	two months extension.....	\$ 390
<input checked="" type="checkbox"/>	three months extension.....	\$ 890
<input type="checkbox"/>	four months extension (not beyond statutory time period).....	\$1390
<input type="checkbox"/>	five months extension	\$1890

Charge **\$890.00** to Deposit Account No. 19-2570. Two copies of this form are enclosed.

Please charge any additional fees under 37 CFR 1.16 or 1.17 which may be required by this
paper, or credit any overpayment, to Deposit Account No. 19-2570. Also, should the Patent and
Trademark Office determine that the fee calculated in the above extension petition is not deemed
sufficient to have this response considered as being timely filed, this constitutes a petition for
extension of time for the minimum period to effect timely filing, and the Commissioner is authorized
to debit any necessary fee to said deposit account.

Respectfully submitted,

William T. Han

William T. Han
Attorney for Applicants
Registration No. 34,344

GLAXOSMITHKLINE

Corporate Intellectual Property - UW2220

P.O. Box 1539

King of Prussia, PA 19406-0939

Phone (610) 270-5219

Facsimile (610) 270-5090

N:\HAN\APPS\P30693-C4\Transmittal Extension of Time.doc

09/193,130

"EXPRESS MAIL CERTIFICATE"
"EXPRESS MAIL" MAILING LABEL NUMBER EL 737 870 959 US
DATE OF DEPOSIT 8/3/01

Attorney Docket No.: P30693C4C1

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: MacPhee, et al. 03 August 2001
Serial No.: Not Yet Assigned Group Art Unit No.: Not Yet Assigned
Filed: Herewith Examiner: Not Yet Assigned
For: Lipoprotein Associated Phospholipase A2 Inhibitors Thereof and Use of
the Same in Diagnosis and Therapy

**STATEMENT TO SUPPORT FILING AND SUBMISSION IN ACCORDANCE
WITH 37 CFR §§ 1.821 THROUGH 1.825**

BOX SEQUENCE

Assistant Commissioner for Patents
Washington, D.C. 20231

- (X) I hereby state that the contents of the paper and computer readable copies of the Sequence Listing transferred from Application Serial Number 09/193,130, filed November 17, 1998, submitted in accordance with **37 CFR §1.821(c)** and **(e)**, respectively, are the same.
- () I hereby state that the submission filed in accordance with **37 CFR §1.821 (g)** does not include new matter.
- () I hereby state that the submission filed in accordance with **37 CFR §1.821 (h)** does not include new matter or go beyond the disclosure in the international application as filed.
- () I hereby state that the amendments, made in accordance with **37 CFR §1.825 (a)**, included in the substitute sheet(s) of the Sequence Listing are supported in the application, as filed, at pages _____. I hereby state that the substitute sheet(s) of the Sequence Listing does (do) not include new matter.
- () I hereby state that the substitute copy of the computer readable form, submitted in accordance with **37 CFR §1.825(b)**, is the same as the amended Sequence Listing.

09/193,130

GLAXOSMITHKLINE
Corporate Intellectual Property - UW2220
P.O. Box 1539
King of Prussia, PA 19406-0939
Phone (610) 270-5219
Facsimile (610) 270-5090
N:\HAN\APPS\VP30693-C4\statsupp.doc